AR046620A1 - Pentafluorosulfanilbenzoilguanidinas, procedimiento para su preparacion, su uso como medicamento o coadyuvante de diagnostico, y medicamento que las comprende - Google Patents
Pentafluorosulfanilbenzoilguanidinas, procedimiento para su preparacion, su uso como medicamento o coadyuvante de diagnostico, y medicamento que las comprendeInfo
- Publication number
- AR046620A1 AR046620A1 ARP040104156A ARP040104156A AR046620A1 AR 046620 A1 AR046620 A1 AR 046620A1 AR P040104156 A ARP040104156 A AR P040104156A AR P040104156 A ARP040104156 A AR P040104156A AR 046620 A1 AR046620 A1 AR 046620A1
- Authority
- AR
- Argentina
- Prior art keywords
- zero
- alkyl
- hydrogen
- alkoxy
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
- A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
Abstract
Son adecuados, por ejemplo, como medicamentos antiarrítmicos con un componente cardioprotector para la profilaxis del infarto y el tratamiento del infarto y para el tratamiento de la angina de pecho. También inhiben de forma preventiva los procesos patofisiológicos asociados con el desarrollo de lesiones inducidas por isquemia, especialmente en el desencadenamiento de arritmias cardíacas inducidas por isquemia. Reivindicación 1: Un compuesto de la fórmula (1), en la que: R1 es hidrógeno, alquilo C1-4, alcoxi C1-4, F, Cl, Br, I, -CN, NR5R6, -Op-(CH2)n-(CF2)o-CF3 o -(SOm)q-(CH2)r-(CF2)s-CF3; R5 y R6 son, independientemente uno de otro, hidrógeno, alquilo C1-4 o -CH2-CF3; m es cero, 1 ó 2; n, o, p, q, r y s son, independientemente uno de otro, cero ó 1; R2 es hidrógeno, alquilo C1-4, alcoxi C1-4, F, Cl, Br, I, -CN, NR7R8, -Ot-(CH2)u-(CF2)v-CF3 o -(SOw)x-(CH2)y-(CF2)z-CF3; R7 y R8 son, independientemente uno de otro, hidrógeno, alquilo C1-4 o -CH2-CF3; m es cero, 1 ó 2; t, u, v, w, x, y y z son, independientemente uno de otro, cero ó 1; R3 es Cl, Br, I, -CN, -SO2CH3, alcoxi C1-4, NR9R10, -Oa-(CH2)b-(CF2)c-CF3, -(SOd)e-(CH2)f-(CF2)g-CF3, alquilo C1-6 o cicloalquilo C3-8, en que 1, 2, 3 ó 4 átomos de hidrógeno pueden estar reemplazados por átomos de flúor; R9 y R10 son, independientemente uno de otro, hidrógeno, alquilo C1-4 o -CH2-CF3; a, b y c son, independientemente uno de otro, cero ó 1; d es cero, 1 ó 2; e es cero ó 1; f es cero, 1, 2, 3 ó 4; g es cero ó 1; o R3 es -(CH2)h-fenilo o -O-fenilo, en que los radicales fenilo no están sustituidos o están sustituidos con 1, 2 ó 3 radicales seleccionados del grupo que consiste en F, Cl, Br, I, -Oj-(CH2)k-CF3, alcoxi C1-4, alquilo C1-4, y -SO2CH3; j es cero ó 1; k es cero, 1, 2 ó 3; h es cero, 1, 2, 3 ó 4; o R3 es -(CH2)aa-heteroarilo, que no está sustituido o está sustituido con 1, 2 ó 3 radicales seleccionados del grupo que consiste en F, Cl, Br, I, -Obb-(CH2)cc-CF3, alcoxi C1-4 y alquilo C1-4 y -SO2CH3; bb es cero ó 1; cc es cero, 1, 2 ó 3; aa es cero, 1, 2, 3 ó 4; R4 es hidrógeno, F, Cl, Br, I, -CN, -SO2CH3, alcoxi C1-4, NR11R12, -Odd-(CH2)ee-(CF2)ff-CF3, -(SOgg)hh-(CH2)jj-(CF2)kk-CF3, alquilo C1-6 o cicloalquilo C3-8, en que 1, 2, 3 ó 4 átomos de hidrógeno pueden estar reemplazados por átomos de flúor; R11 y R12 son, independientemente uno de otro, hidrógeno, alquilo C1-4 o -CH2-CF3; dd, ee y ff son, independientemente uno de otro, cero ó 1; gg es cero, 1 ó 2; hh es cero ó 1; jj es cero, 1, 2, 3 ó 4; kk es cero ó 1; o R4 es -(CH2)ll-fenilo o -O-fenilo, en que los radicales fenilo no están sustituidos o están sustituidos con 1, 2 ó 3 radicales seleccionados del grupo que consiste en F, Cl, Br, I, -Omm-(CH2)nn-CF3, alcoxi C1-4, alquilo C1-4 y -SO2CH3; mm es cero ó 1; nn es cero, 1, 2 ó 3; ll es cero, 1, 2, 3 ó 4; o R4 es -(CH2)oo-heteroarilo, que no está sustituido o está sustituido con 1, 2 ó 3 radicales seleccionados del grupo que consiste en F, Cl, Br, I, -Opp-(CH2)rr-CF3, alcoxi C1-4 y alquilo C1-4 y -SO2CH3; pp es cero ó 1; rr es cero, 1, 2 ó 3; oo es cero, 1, 2, 3 ó 4; y sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10353202A DE10353202A1 (de) | 2003-11-13 | 2003-11-13 | Pentafluorsulfuranyl-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046620A1 true AR046620A1 (es) | 2005-12-14 |
Family
ID=34585094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040104156A AR046620A1 (es) | 2003-11-13 | 2004-11-11 | Pentafluorosulfanilbenzoilguanidinas, procedimiento para su preparacion, su uso como medicamento o coadyuvante de diagnostico, y medicamento que las comprende |
Country Status (39)
| Country | Link |
|---|---|
| EP (1) | EP1685096B1 (es) |
| JP (1) | JP4528304B2 (es) |
| KR (1) | KR101262065B1 (es) |
| CN (1) | CN100445265C (es) |
| AR (1) | AR046620A1 (es) |
| AT (1) | ATE368029T1 (es) |
| AU (1) | AU2004288758B2 (es) |
| BR (1) | BRPI0416487A (es) |
| CA (1) | CA2551057C (es) |
| CR (1) | CR8321A (es) |
| CY (1) | CY1106868T1 (es) |
| DE (2) | DE10353202A1 (es) |
| DK (1) | DK1685096T3 (es) |
| DO (1) | DOP2004001028A (es) |
| EC (1) | ECSP066563A (es) |
| ES (1) | ES2287788T3 (es) |
| GT (1) | GT200400217A (es) |
| HK (1) | HK1095584A1 (es) |
| HN (1) | HN2004000474A (es) |
| HR (1) | HRP20070364T3 (es) |
| IL (1) | IL175237A (es) |
| JO (1) | JO2466B1 (es) |
| MA (1) | MA28161A1 (es) |
| MY (1) | MY144211A (es) |
| NI (1) | NI200600112A (es) |
| NO (1) | NO20062635L (es) |
| NZ (1) | NZ547172A (es) |
| OA (1) | OA13285A (es) |
| PE (1) | PE20051034A1 (es) |
| PL (1) | PL1685096T3 (es) |
| PT (1) | PT1685096E (es) |
| RS (1) | RS50520B (es) |
| RU (1) | RU2380358C2 (es) |
| TN (1) | TNSN06116A1 (es) |
| TW (1) | TWI334411B (es) |
| UA (1) | UA84307C2 (es) |
| UY (1) | UY28616A1 (es) |
| WO (1) | WO2005047239A1 (es) |
| ZA (1) | ZA200602579B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7317124B2 (en) * | 2003-11-13 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Ortho-substituted pentafluorosulfanylbenzenes, process for their preparation and their use as valuable synthetic intermediates |
| ES2400322T3 (es) | 2008-02-05 | 2013-04-09 | Sanofi | Derivados de SF5 como inhibidores de PAR-1, su preparación y utilización como medicamento |
| WO2012094451A1 (en) * | 2011-01-06 | 2012-07-12 | Beta Pharma Canada Inc. | Novel ureas for the treatment and prevention of cancer |
| CN106414402A (zh) | 2013-11-01 | 2017-02-15 | 宇部兴产株式会社 | 丙烯酰(氧基或氨基)五氟硫烷基苯化合物、其药学可接受的盐及其前药 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2097409T3 (es) * | 1992-09-22 | 1997-04-01 | Hoechst Ag | Benzoilguanidinas, procedimiento para su preparacion, asi como su empleo como antiarritmicos. |
| DE4417004A1 (de) * | 1994-05-13 | 1995-11-16 | Hoechst Ag | Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19517848A1 (de) * | 1995-05-16 | 1996-11-21 | Merck Patent Gmbh | Fluorhaltige Benzoylguanidine |
| DE19526381A1 (de) * | 1995-07-19 | 1997-01-23 | Hoechst Ag | 4-Fluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19713427A1 (de) * | 1997-04-01 | 1998-10-08 | Hoechst Ag | Ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19950898A1 (de) * | 1999-10-22 | 2001-04-26 | Aventis Pharma Gmbh | Heterocyclisch substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE10222192A1 (de) * | 2002-05-18 | 2003-11-27 | Aventis Pharma Gmbh | Pentafluorsulfuranyl-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE10338554A1 (de) * | 2003-08-22 | 2005-03-31 | Aventis Pharma Deutschland Gmbh | Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
-
2003
- 2003-11-03 OA OA1200600153A patent/OA13285A/en unknown
- 2003-11-13 DE DE10353202A patent/DE10353202A1/de not_active Withdrawn
-
2004
- 2004-10-06 JO JO2004140A patent/JO2466B1/en active
- 2004-10-27 GT GT200400217A patent/GT200400217A/es unknown
- 2004-11-03 RS RSP-2007/0368A patent/RS50520B/sr unknown
- 2004-11-03 RU RU2006120448/04A patent/RU2380358C2/ru not_active IP Right Cessation
- 2004-11-03 AT AT04797535T patent/ATE368029T1/de active
- 2004-11-03 PL PL04797535T patent/PL1685096T3/pl unknown
- 2004-11-03 ES ES04797535T patent/ES2287788T3/es active Active
- 2004-11-03 DE DE502004004460T patent/DE502004004460D1/de active Active
- 2004-11-03 PT PT04797535T patent/PT1685096E/pt unknown
- 2004-11-03 CN CNB200480033483XA patent/CN100445265C/zh not_active Expired - Fee Related
- 2004-11-03 AU AU2004288758A patent/AU2004288758B2/en not_active Ceased
- 2004-11-03 EP EP04797535A patent/EP1685096B1/de active Active
- 2004-11-03 CA CA2551057A patent/CA2551057C/en not_active Expired - Fee Related
- 2004-11-03 NZ NZ547172A patent/NZ547172A/en not_active IP Right Cessation
- 2004-11-03 UA UAA200606449A patent/UA84307C2/ru unknown
- 2004-11-03 WO PCT/EP2004/012393 patent/WO2005047239A1/de active Application Filing
- 2004-11-03 DK DK04797535T patent/DK1685096T3/da active
- 2004-11-03 JP JP2006538730A patent/JP4528304B2/ja not_active Expired - Fee Related
- 2004-11-03 BR BRPI0416487-3A patent/BRPI0416487A/pt not_active IP Right Cessation
- 2004-11-10 DO DO2004001028A patent/DOP2004001028A/es unknown
- 2004-11-11 HN HN2004000474A patent/HN2004000474A/es unknown
- 2004-11-11 AR ARP040104156A patent/AR046620A1/es not_active Application Discontinuation
- 2004-11-11 TW TW093134390A patent/TWI334411B/zh not_active IP Right Cessation
- 2004-11-12 UY UY28616A patent/UY28616A1/es not_active Application Discontinuation
- 2004-11-12 PE PE2004001110A patent/PE20051034A1/es not_active Application Discontinuation
- 2004-11-12 MY MYPI20044737A patent/MY144211A/en unknown
-
2006
- 2006-03-29 ZA ZA200602579A patent/ZA200602579B/xx unknown
- 2006-03-31 CR CR8321A patent/CR8321A/es unknown
- 2006-04-21 TN TNP2006000116A patent/TNSN06116A1/en unknown
- 2006-04-26 IL IL175237A patent/IL175237A/en not_active IP Right Cessation
- 2006-05-11 EC EC2006006563A patent/ECSP066563A/es unknown
- 2006-05-11 KR KR1020067009186A patent/KR101262065B1/ko not_active IP Right Cessation
- 2006-05-12 NI NI200600112A patent/NI200600112A/es unknown
- 2006-05-12 MA MA29028A patent/MA28161A1/fr unknown
- 2006-06-08 NO NO20062635A patent/NO20062635L/no unknown
-
2007
- 2007-03-08 HK HK07102568.1A patent/HK1095584A1/xx not_active IP Right Cessation
- 2007-08-23 HR HR20070364T patent/HRP20070364T3/xx unknown
- 2007-09-14 CY CY20071101190T patent/CY1106868T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR048039A1 (es) | Profarmacos de piperazina y agentes antivirales de piperidina sustituidos | |
| AR058379A1 (es) | Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas. | |
| CO2019011604A2 (es) | Compuestos inhibidores de vmat2, composiciones y métodos relativos a los mismos | |
| RU2015148010A (ru) | Высокоактивное производное нуклеозида для лечения hcv | |
| AR055070A1 (es) | Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso | |
| AR064304A1 (es) | Formulaciones de ansamicina y sus metodos de uso | |
| AR028985A1 (es) | Compuestos derivados de quinolin-2-ona- sustituidos con heteroarilo utiles como agentes anticancerigenos, procedimiento de tratamiento de enfermedades utilizando dicho compuesto, composicion farmaceutica que lo contiene | |
| AR067759A1 (es) | Compuestos de pirazol utiles como moduladores de la enzima raf asociada al crecimiento celular anormal | |
| AR074543A1 (es) | Derivados de imidazo[1,2-a]piridin-2-il, agonistas de receptores 1-fosfato de esfingosina(1s1p1), composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes | |
| AR054482A1 (es) | Derivados de azetidinona para el tratamiento de hiperlipidemias | |
| DOP2002000422A (es) | Agentes antibacterianos. | |
| PA8574701A1 (es) | Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen | |
| AR031226A1 (es) | 1,1'-bifenil-2-carboxamidas 2'-sustituidas, procesos para su preparacion, su uso para la manufactura de un medicamento, y composiciones farmaceuticas que las contienen | |
| ECSP044999A (es) | Agentes antidiabeticos | |
| AR039689A1 (es) | Difenilazetidinonas sustituidas, medicamentos que comprenden estos compuestos y su uso | |
| CO6690783A2 (es) | Combinaciones que contienen n-(2-arilamino)arilsulfonamida sustituida | |
| AR053339A1 (es) | Composiciones para el tratamiento del cabello y/o del cuero cabelludo | |
| CO2021017435A2 (es) | Analogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida | |
| AR043444A1 (es) | Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2 | |
| AR040034A1 (es) | Pentafluorosulfanilbenzoilguanidinas, procedimiento para su preparacion, su uso como medicamento o compuesto auxiliar de diagnostico, y un medicamento que las comprende | |
| UY27685A1 (es) | Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso | |
| AR046620A1 (es) | Pentafluorosulfanilbenzoilguanidinas, procedimiento para su preparacion, su uso como medicamento o coadyuvante de diagnostico, y medicamento que las comprende | |
| PE20100154A1 (es) | Pregn-4-en-21,17-carbolactonas sustituidas en el anillo c, asi como preparados farmaceuticos que las contienen | |
| UY29394A1 (es) | Derivados sustituidos de n-(5-(2-propilamino.1.hidroxietil)-2-hdroxifenil) metano sulfonamida, composiciones farmacéuticas que lo contienen y aplicaciónes. | |
| AR112900A1 (es) | Compuesto derivado de pirazol y uso de este |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |